Circumventing the requirement of binding saturation for receptor quantification using interaction kinetic extrapolation

被引:12
作者
Barta, Pavel [2 ,3 ]
Bjorkelund, Hanna [1 ,2 ]
Andersson, Karl [1 ,2 ]
机构
[1] Ridgeview Instruments AB, SE-75643 Uppsala, Sweden
[2] Uppsala Univ, Dept Radiol,Oncol & Radiat Sci, Uppsala, Sweden
[3] Charles Univ Prague, Dept Pharmacol & Toxicol, Fac Pharm Hradec Kralove, Prague, Czech Republic
关键词
kinetics; ligand-receptor interaction; receptor quantification;
D O I
10.1097/MNM.0b013e3283483e1c
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Quantification of the number of receptors per cell (NRPC) is important when assessing whether a tumor surface biomarker is suitable for medical imaging. One common method for NPRC quantification is to use a binding saturation assay, which is time consuming and requires large amounts of reagents. The aim of this study was to evaluate an alternative method based on kinetic extrapolation (KEX) and compare it with the classical manual saturation technique with regard to accuracy as well as time and reagent consumption. Epidermal growth factor receptor (EGFR) and HER2 receptor surface expression were quantified on five tumor cell lines using three (125)I-labeled and (131)I-labeled ligands (cetuximab and EGF for EGFR, trastuzumab for HER2 receptor) for both techniques. The KEX method involved interaction measurements in the LigandTracer, followed by KEX through computerized real-time interaction analysis to correct for nonsaturation on cells. Variability and NRPC estimates of the EGFR and HER2 receptor levels using the KEX method were comparable with the results from the classical saturation technique. However, the ligand consumption for the KEX method was 26-46% of the classical saturation technique. Furthermore, the KEX method reduced the workload radically. From the observations described in this study, we believe that the KEX method enables fast, credible, and easy NRPC quantification with a reduction in reagent consumption. Nucl Med Commun 32: 863-867 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:863 / 867
页数:5
相关论文
共 10 条
[1]   EPIDERMAL GROWTH-FACTOR RECEPTORS [J].
ADAMSON, ED ;
REES, AR .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 1981, 34 (03) :129-152
[2]  
Andersson K, 2010, ANTIBODY ANTIGEN INT
[3]   Measuring the affinity of a radioligand with its receptor using a rotating cell dish with in situ reference area [J].
Björke, H ;
Andersson, K .
APPLIED RADIATION AND ISOTOPES, 2006, 64 (01) :32-37
[4]   Avoiding false negative results in specificity analysis of protein-protein interactions [J].
Bjorkelund, Hanna ;
Gedda, Lars ;
Andersson, Karl .
JOURNAL OF MOLECULAR RECOGNITION, 2011, 24 (01) :81-89
[5]   FLOW CYTOMETRIC METHOD FOR THE MEASUREMENT OF EPIDERMAL GROWTH-FACTOR RECEPTOR AND COMPARISON WITH THE RADIO-LIGAND BINDING ASSAY [J].
BROTHERICK, I ;
LENNARD, TWJ ;
WILKINSON, SE ;
COOK, S ;
ANGUS, B ;
SHENTON, BK .
CYTOMETRY, 1994, 16 (03) :262-269
[6]   PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY [J].
GREENWOOD, FC ;
HUNTER, WM .
BIOCHEMICAL JOURNAL, 1963, 89 (01) :114-&
[7]   Testing for HER2 status [J].
Hanna, W .
ONCOLOGY, 2001, 61 :22-30
[8]   Ligand binding assays at equilibrium: validation and interpretation [J].
Hulme, Edward C. ;
Trevethick, Mike A. .
BRITISH JOURNAL OF PHARMACOLOGY, 2010, 161 (06) :1219-1237
[9]   Effect of cetuximab treatment in squamous cell carcinomas [J].
Nestor, Marika .
TUMOR BIOLOGY, 2010, 31 (02) :141-147
[10]  
Persson MI, 2006, ONCOL REP, V15, P673